1. What is the decision or change (e.g. clinical topic, practice guideline, system design, delivery of care) you are facing or struggling with where a summary of the evidence would be helpful?
Given the emergence of new antiseizure medications and the wide clinical variability in management of patients with Lennox-Gastaut Syndrome (LGS), the American Epilepsy Society (AES) and its members are interested in the most appropriate nonpharmacological and pharmacological therapies in treating seizures in patients with LGS.
2. Why are you struggling with this issue?
There is wide variability in practice, especially since the emergence of new therapies. The new therapies are more expensive, but do they offer better value for patients and society as a whole.
3. What do you want to see changed? How will you know that your issue is improving or has been addressed?
A systematic review of the literature, potentially supp orting AES clinical guidance, will establish the best practice for treatment of patients with LGS. Clinical guidance will advance providers' and patients' understanding of which treatment options are better than others, and when nonmedical/surgical treatment options are appropriate.
4. When do you need the evidence report?
5. What will you do with the evidence report?
The AES Guidelines and Assessment Committee (GAC) will review the evidence report as a basis for clinical guidance development. Moreover, educational programs around the evidence report will be created, both during the annual meeting of the AES and for online education.
While AES members feel the need for an evidence review as soon as possible, AES understands the time needed for conducting a rigorous evidence review. If the topic is selected, the AES GAC will use the up to 2-year timeframe to organize resources and prepare for prompt clinical guidance implementation activities. For this reason, there is flexibility in the date suggested in the prior question.
Please see the attached summary of AES and the resources it brings to translation of an evidence review to clinical guidance as well as advancing dissemination and implementation of results through an extensive multidisciplinary network.
AES and the GAC welcome the opportunity to discuss the need for this topic in more depth and to connect AHRQ with its member volunteer topic experts as well as representatives from its patient stakeholder network, as needed in further exploring the topic and/or development of the evidence review, should the topic be selected.
About the American Epilepsy Society (AES) (PDF, 154 KB)
Optional Information About You
What is your role or perspective? Professional society
If you are you making a suggestion on behalf of an organization, please state the name of the organization American Epilepsy Society
May we contact you if we have questions about your nomination? Yes